TSX gains after CPI shows US inflation rose 3%
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), currently trading at $2.38 and down nearly 98% year-to-date according to InvestingPro data, reported Thursday that it amended its Securities Purchase Agreement with accredited investors to add an additional buyer and increase the size of its initial closing by $500,000, bringing total gross proceeds for the initial closing to approximately $2.25 million. The adjustment reduces the size of subsequent closings by the same amount, with the aggregate funding under the agreement remaining at up to $7 million.
According to a press release statement, on October 14, 2025, Cero Therapeutics filed a Certificate of Designations to establish its Series E convertible preferred stock. The filing was made in connection with the Securities Purchase Agreement dated October 14, 2025. The Certificate of Designations became effective the same day.
On Thursday, the company and the participating investors completed the initial closing, issuing 3,816 shares of Series E Preferred Stock for gross proceeds of $2.25 million. The remaining $4.75 million of the $7 million total is expected to be funded in additional closings under the terms of the agreement.
The Series E Preferred Stock was offered and sold in reliance on exemptions from registration under the Securities Act of 1933, as amended, and similar state laws. The rights and preferences of the Series E Preferred Stock are set forth in the Certificate of Designations filed as part of the SEC submission.
Cero Therapeutics’ common stock and warrants are listed on the Nasdaq Capital Market under the symbols CERO and CEROW, respectively.
This information is based on a statement provided in a recent SEC filing.
In other recent news, CERo Therapeutics Holdings, Inc. has completed the first cohort of its Phase 1 clinical trial for CER-1236, targeting acute myeloid leukemia (AML). The trial’s Dose Escalation Safety Committee has given the green light to begin the second cohort, following the observation of cell expansion with no dose-limiting toxicities. This second cohort will receive a higher starting dosage compared to the first group. Additionally, CERo Therapeutics has dosed the third patient in the initial cohort, which may conclude pending safety assessments. The company has also secured a Notice of Allowance from the U.S. Patent and Trademark Office for a patent that will protect the composition of matter for CER-1236 through 2041. This patent will cover its use in cancer treatment, offering significant protection for CERo’s lead product candidate. Moreover, CERo has received a patent in Japan, safeguarding its CER platform technology. Axios reports that CERo Therapeutics is open to licensing deals or a potential sale as it awaits key data on its lead asset.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.